New approaches to clinical trials in vascular dementia: Memantine in small vessel disease

Cerebrovascular Diseases

Volumn 13, Issue SUPPL. 2, 2002, Pages 61-66

  Möbius, Hans Jörg ^a   Stoffler A ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Memantine; Randomized controlled trial; Small vessel disease; Subcortical dementia; Vascular dementia

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG INDICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NEURORADIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE;

AGED; COGNITION; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MAGNETIC RESONANCE IMAGING; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036130174     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049153     Document Type: Article

References (30)

1. Vascular dementia: An obsolete concept
2. Vascular dementia: The role of cerebral infarcts
3. Research criteria for subcortical vascular dementia in clinical trials
4. Subcortical vascular dementia as a specific target for clinical trials
5. Senile dementia of the Binswanger type. A vascular form of dementia in the elderly
6. Alzheimer's disease and vascular dementia. Some points of confluence
7. Overlap between pathology of Alzheimer disease and vascular dementia
8. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales
9. A new rating scale for Alzheimer's disease
10. Cognitive outcome measures
11. The cognitive syndrome of vascular dementia: Implications for clinical trials
12. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia
13. A multicentre randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia
14. A 24-month, double-blind, placebo-controlled multi-centre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis
15. Treatment of chronic cerebrovascular disease in elderly patients with pentoxifylline
16. Pentoxifylline in cerebrovascular dementia
17. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM-III-R
18. Clinical trials of propentofylline in vascular dementia
19. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials
20. Posatirelin in the treatment of vascular dementia: A double-blind multicentre study vs. placebo
21. An efficacy and safety analysis of Exelon® in Alzheimer's disease patients with concurrent vascular risk factors
22. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the scandinavian multi-infarct dementia trial
23. Efficacy of memantine in mild to moderate vascular dementia (the MMM 300 Trial)
24. Cognitive improvement by memantine in a placebo-controlled trial in mild to moderate vascular dementia (the MMM 500 Trial)
25. Neuroradiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia
26. Infusion of (+)-MK-801 and memantine - Contrasting effects on radial maze learning in rats with entorhinal cortex lesion
27. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats
28. Pharmacological rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia
29. Memantine in moderately severe to severe Alzheimer's disease: Results of a placebo-controlled 6-month trial
30. Neuroprotection and symptomatological action of memantine relevant for Alzheimer's disease - A unified hypothesis on the mechanism of action